300529SZSE
🚨 Material Event

2026 Semi-Annual Report

Jafron Biomedical Co., Ltd.··179 pages

✨ AI Summary

Jafron Biomedical Co., Ltd. has released its 2026 semi-annual report. The company confirms the accuracy and completeness of the financial statements and declares that no cash dividends, bonus shares, or capital reserve conversions will be issued for this period. The report includes detailed management discussions, analysis of risks, and corporate governance disclosures.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

[Chart: Jafron logo]

Jafron Biomedical Co., Ltd.

2026 Semi-Annual Report

August 2026

Stock Code: 300529 Stock Abbreviation: Jafron Biomedical Announcement No.: 2026-045

Bond Code: 123117 Bond Abbreviation: Jafron Convertible Bonds

Section I: Important Notices, Table of Contents, and Definitions

The Board of Directors, the Board of Supervisors, and the directors, supervisors, and senior management of the Company guarantee that the information in this semi-annual report is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions. They assume individual and joint legal liability for the content.

Company Chairman Dong Fan, Chief Financial Officer Liao Xueyun, and Head of Accounting Department (Accounting Supervisor) Li Ziyun declare: We guarantee the truth, accuracy, and completeness of the financial statements in this semi-annual report.

All directors attended the board meeting to review this semi-annual report.

This report contains forward-looking statements regarding business plans, future plans, and development strategies, which do not constitute substantive commitments or profit forecasts by the Company to investors. Realization depends on market conditions and other factors; investors are advised to be aware of investment risks.

The Company has detailed the potential risk factors and countermeasures for its future development in this report. Please refer to "Section III: Management Discussion and Analysis" under "X. Risks Faced by the Company and Countermeasures." Investors are advised to be aware of investment risks.

The Company plans not to distribute cash dividends, not to issue bonus shares, and not to convert capital reserves into share capital.

Table of Contents

SectionPage
Section I: Important Notices, Table of Contents, and Definitions2
Section II: Company Profile and Key Financial Indicators6
Section III: Management Discussion and Analysis9
Section IV: Corporate Governance, Environment, and Society26
Section V: Important Matters28
Section VI: Changes in Shares and Shareholders32
Section VII: Bond-Related Information38
Section VIII: Financial Report42

List of Documents Available for Inspection

  1. Financial statements signed and sealed by the Company's legal representative, the person in charge of accounting, and the head of the accounting department.

  2. Originals of all company documents and announcements publicly disclosed on the website designated by the CSRC during the reporting period.

Location of the above documents: Office of the Board Secretary.

Definitions

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.